Anika Therapeutics, Inc. (ANIK) Operating Margin
- Operating margin · 12 months: Value -4.24%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4.24% | Operating income / revenue. Period ending 2026-06-30. $-5.12M ÷ $120.65M × 100 ≈ -4.24% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -5.12M USD | Operating Income (Loss) |
| Revenue | 120.65M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 45.65M USD | Cost of Goods and Services Sold |
| Research and development | 27.45M USD | Research and Development Expense |
| Selling, general and administration | 52.67M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-5.12M | $120.65M | $45.65M | $27.45M | $52.67M | -4.24% |
| 2026-03-31 | $-12.26M | $116.26M | $48.14M | $26.42M | $53.95M | -10.54% |
| 2025-12-31 | $-11.05M | $112.82M | $49.01M | $25.77M | $49.09M | -9.80% |
| 2025-09-30 | $-12.40M | $112.81M | $51.05M | $25.82M | $48.33M | -10.99% |
| 2025-06-30 | $-9.25M | $114.55M | $48.97M | $24.82M | $50.00M | -8.08% |
| 2025-03-31 | $-6.88M | $117.05M | $45.35M | $25.19M | $53.39M | -5.88% |
| 2024-12-31 | $-5.10M | $119.91M | $43.91M | $25.54M | $55.55M | -4.25% |
| 2024-09-30 | $-96.70M | $164.17M | $84.41M | $30.39M | $80.78M | -58.90% |
| 2024-06-30 | $-76.36M | $166.88M | $63.61M | $30.94M | $86.50M | -45.76% |
| 2024-03-31 | $-80.15M | $169.26M | $64.39M | $32.45M | $90.38M | -47.35% |
| 2023-12-31 | $-87.64M | $166.66M | $63.57M | $32.69M | $95.85M | -52.58% |
| 2023-09-30 | $-30.52M | $163.31M | $62.42M | $32.85M | $98.56M | -18.69% |
| 2023-06-30 | $-28.65M | $162.11M | $63.39M | $32.36M | $95.01M | -17.67% |
| 2023-03-31 | $-28.40M | $157.47M | $62.85M | $30.43M | $92.59M | -18.03% |
| 2022-12-31 | $-19.40M | $156.24M | $62.66M | $28.18M | $84.79M | -12.42% |
| 2022-09-30 | $-21.86M | $152.44M | $64.86M | $26.43M | $82.18M | -14.34% |
| 2022-06-30 | $-14.76M | $151.71M | $63.88M | $26.80M | $78.40M | -9.73% |
| 2022-03-31 | $-2.20M | $150.19M | $66.42M | $27.12M | $75.12M | -1.46% |
| 2021-12-31 | $2.62M | $147.79M | $64.85M | $27.33M | $74.10M | 1.77% |
| 2021-09-30 | $-6.21M | $144.66M | $63.11M | $28.96M | $68.84M | -4.30% |
| 2021-06-30 | $-15.44M | $136.82M | $60.95M | $26.50M | $67.25M | -11.29% |
| 2021-03-31 | $-34.16M | $129.35M | $60.55M | $23.74M | $63.81M | -26.41% |
| 2020-12-31 | $-28.32M | $130.46M | $61.43M | $23.43M | $60.06M | -21.71% |
| 2020-09-30 | $-5.57M | $127.54M | $54.14M | $19.88M | $57.12M | -4.36% |
| 2020-06-30 | $14.41M | $125.54M | $45.74M | $18.82M | $48.76M | 11.48% |
| 2020-03-31 | $35.86M | $125.28M | $35.64M | $18.46M | $41.71M | 28.62% |
| 2019-12-31 | $34.25M | $114.61M | $28.75M | $16.66M | $34.95M | 29.88% |
| 2019-09-30 | $39.21M | $111.79M | $27.10M | $16.64M | $28.84M | 35.07% |
| 2019-06-30 | $35.73M | $108.88M | $29.43M | $16.72M | $27.00M | 32.82% |
| 2019-03-31 | $35.06M | $109.01M | $30.75M | $17.29M | $25.92M | 32.16% |
| 2018-12-31 | $21.75M | $105.56M | $31.28M | $18.19M | $34.34M | 20.60% |
| 2018-09-30 | $21.71M | (m) | (m) | $18.39M | $34.88M | (m) |
| 2018-06-30 | $23.41M | (m) | (m) | $20.00M | $34.01M | (m) |
| 2018-03-31 | $29.89M | (m) | (m) | $19.72M | $32.56M | (m) |
| 2017-12-31 | $45.73M | $113.42M | (m) | $18.79M | $21.54M | 40.32% |
| 2017-09-30 | $48.74M | $112.76M | (m) | $17.48M | $20.35M | 43.23% |
| 2017-06-30 | $52.16M | $111.36M | (m) | $14.46M | $19.81M | 46.84% |
| 2017-03-31 | $47.90M | $104.48M | (m) | $12.80M | $19.09M | 45.85% |
| 2016-12-31 | $50.61M | $103.38M | (m) | $10.73M | $18.01M | 48.95% |
| 2016-09-30 | $54.93M | $105.55M | (m) | $10.79M | $17.05M | 52.05% |
| 2016-06-30 | $54.38M | $103.44M | (m) | $10.03M | $16.08M | 52.57% |
| 2016-03-31 | $53.34M | $99.76M | (m) | $9.05M | $15.21M | 53.47% |
| 2015-12-31 | $48.13M | $93.00M | (m) | $8.99M | $14.82M | 51.76% |
| 2015-09-30 | $43.16M | $85.36M | (m) | $7.96M | $13.97M | 50.56% |
| 2015-06-30 | $40.31M | $83.73M | (m) | $7.89M | $14.71M | 48.14% |
| 2015-03-31 | $43.08M | $87.10M | (m) | $7.95M | $15.19M | 49.46% |
| 2014-12-31 | $61.45M | $105.59M | (m) | $8.14M | $15.07M | 58.19% |
| 2014-09-30 | $59.79M | $103.59M | (m) | $8.19M | $13.80M | 57.72% |
| 2014-06-30 | $57.27M | $99.29M | (m) | $7.81M | $12.95M | 57.68% |
| 2014-03-31 | $51.47M | $93.84M | (m) | $7.76M | $12.48M | 54.84% |
| 2013-12-31 | $32.61M | $75.08M | (m) | $7.06M | $12.94M | 43.43% |
| 2013-09-30 | $29.97M | $76.44M | (m) | $6.37M | $14.20M | 39.21% |
| 2013-06-30 | $24.93M | $73.45M | (m) | $5.97M | $14.62M | 33.94% |
| 2013-03-31 | $21.66M | $72.24M | (m) | $5.44M | $15.32M | 29.99% |
| 2012-12-31 | $19.72M | $71.36M | (m) | $5.39M | $14.73M | 27.63% |
| 2012-09-30 | $16.84M | $67.20M | (m) | $5.58M | $15.93M | 25.06% |
| 2012-06-30 | $18.93M | $70.89M | (m) | $5.89M | $17.04M | 26.71% |
| 2012-03-31 | $16.47M | $67.40M | (m) | $6.17M | $17.17M | 24.44% |
| 2011-12-31 | $13.97M | $64.78M | (m) | $6.17M | $17.86M | 21.56% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $7.54M | $55.56M | (m) | $6.87M | $17.32M | 13.57% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $5.59M | $40.14M | (m) | $8.18M | $10.55M | 13.92% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |